Standout Papers

Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth facto... 2021 2026 2022 2024150
  1. Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival (2021)
    Dennis J. Slamon, Patrick Neven et al. Annals of Oncology

Immediate Impact

2 from Science/Nature 55 standout
Sub-graph 1 of 23

Citing Papers

The hallmarks of cancer immune evasion
2024 Standout
Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2– and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study
2024 Standout
3 intermediate papers

Works of Arnd Nusch being referenced

Overall survival (OS) in patients (pts) with advanced breast cancer (ABC) with visceral metastases (mets), including those with liver mets, treated with ribociclib (RIB) plus endocrine therapy (ET) in the MONALEESA (ML) -3 and -7 trials.
2020
Patient-reported outcomes (PROs) in advanced breast cancer (ABC) treated with ribociclib + fulvestrant: Results from MONALEESA-3
2018
and 2 more

Author Peers

Author Last Decade Papers Cites
Arnd Nusch 447 421 204 49 694
Katarzyna Pogoda 380 494 167 49 681
Marcello Ferretti Fanelli 298 404 235 46 678
Alain Livartowski 480 442 256 45 844
Antonio Santo 345 303 106 54 705
Barbara Radecka 289 435 131 57 618
Jian Zhang 225 366 157 57 684
Ruofan Huang 387 412 174 37 707
Hiroyuki Yasojima 324 497 181 50 662
Olga Martínez‐Sáez 326 434 283 60 778
Claudia Andreetta 200 501 291 41 795

All Works

Loading papers...

Rankless by CCL
2026